Delving into the Latest Updates on Flurbiprofen Axetil with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Flurbiprofen axetil (JAN)

+ [5]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Cancer PainPain, PostoperativePain+ [1]

Inactive Indication-

Originator Organization

Kaken Pharmaceutical Co., Ltd.

Active Organization

Kaken Pharmaceutical Co., Ltd.

Beijing Tide Pharmaceutical Co., Ltd.

Shanxi Pude Pharmaceutical Co., Ltd.

+ [2]

Inactive Organization

GUANGDONG JIABO PHARMACEUTICAL CO LTD

Drug Highest PhaseApproved

First Approval Date

JP (27 Mar 1992),

Cancer PainPain, Postoperative

RegulationPriority Review (CN)

Login to view timeline

Structure

Molecular FormulaC19H19FO4

InChIKeyALIVXCSEERJYHU-UHFFFAOYSA-N

CAS Registry91503-79-6

Primary objective: To compare the effectiveness of flurbiprofen axetil injection and the original drug flurbiprofen axetil injection (ROPION®) for postoperative analgesia in subjects. Secondary objective: To compare the safety of flurbiprofen axetil injection and the original drug flurbiprofen axetil injection (ROPION®) for postoperative analgesia in subjects.

Start Date18 Jul 2023

Sponsor / Collaborator

Chongqing Yao Pharmaceutical Co., Ltd.

CTR20223269 / CompletedNot Applicable

评价氟比洛芬酯注射液用于术后镇痛的多中心、随机、双盲、平行、阳性对照临床试验

[Translation] A multicenter, randomized, double-blind, parallel, positive-controlled clinical trial to evaluate the use of flurbiprofen axetil injection for postoperative analgesia

以氟比洛芬酯注射液（ROPION）作为阳性对照，评价氟比洛芬酯注射液用于治疗术后中到重度疼痛时的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of flurbiprofen axetil injection (ROPION) in the treatment of moderate to severe postoperative pain, using flurbiprofen axetil injection as a positive control.

Start Date14 Feb 2023

Sponsor / Collaborator

Yichang Humanwell Pharmaceuticals Co., Ltd.

NCT05577962 / Not yet recruitingNot ApplicableIIT

The Effect of Opioid-free Anesthesia Protocol on the Early Quality of Recovery After Thyroidectomy (TOFA Trial): Study Protocol for a Prospective, Monocentric, Randomized, Single-blinded Trial

To analyze and compare the effect of OFA scheme and traditional balanced anesthesia scheme on QoR15 after thyroidectomy, and further clarify the safety and rationality of OFA scheme in perioperative application of thyroid surgery.

Start Date01 Feb 2023

Sponsor / Collaborator

Beijing Friendship Hospital

100 Clinical Results associated with Flurbiprofen Axetil

Login to view more data

100 Translational Medicine associated with Flurbiprofen Axetil

Login to view more data

100 Patents (Medical) associated with Flurbiprofen Axetil

Login to view more data

184

Literatures (Medical) associated with Flurbiprofen Axetil

01 Oct 2024·Anaesthesia

Comparison of opioid‐free and opioid‐inclusive propofol anaesthesia for thyroid and parathyroid surgery: a randomised controlled trial

Article

Author: Liu, Hong ; Zhu, Ya‐Juan ; Shan, Xi‐Sheng ; Ji, Fu‐Hai ; Wang, Dan ; Sun, Yan ; Peng, Ke

SummaryBackgroundPostoperative nausea and vomiting occur frequently following thyroid and parathyroid surgery and are associated with worse patient outcomes. We hypothesised that opioid‐free propofol anaesthesia would reduce the incidence of postoperative nausea and vomiting compared with opioid‐inclusive propofol anaesthesia in patients undergoing these procedures.MethodsWe conducted a randomised, double‐blinded controlled trial in adult patients scheduled to undergo thyroid and parathyroid surgery at two medical centres in mainland China. Patients were allocated randomly (1:1, stratified by sex and trial site) to an opioid‐free anaesthesia group (esketamine, lidocaine, dexmedetomidine and propofol) or an opioid‐inclusive group (sufentanil and propofol). Propofol infusions were titrated to bispectral index 45–55. Patients received prophylaxis for nausea and vomiting using dexamethasone and ondansetron and multimodal analgesia with paracetamol and flurbiprofen axetil. The primary outcome was the incidence of postoperative nausea and vomiting in the first 48 h after surgery.ResultsWe assessed 557 patients for eligibility and 394 completed this trial. The incidence of postoperative nausea and vomiting in the first postoperative 48 h was lower in the opioid‐free anaesthesia group (10/197, 5%) compared with opioid‐inclusive group (47/197, 24%) (OR (95%CI) 0.17 (0.08–0.35), p < 0.001), yielding a number needed to treat of 5.3. Additionally, opioid‐free propofol anaesthesia was associated with a reduced need for rescue anti‐emetics, lower rates of hypotension and desaturation after tracheal extubation, and higher patient satisfaction. Time to tracheal extubation was prolonged slightly in the opioid‐free group. The two groups had similar postoperative pain scores and 30‐day outcomes.DiscussionOpioid‐free propofol anaesthesia reduced postoperative nausea and vomiting in patients undergoing thyroid and parathyroid surgery. An opioid‐free anaesthetic regimen can optimise anaesthetic care during thyroid and parathyroid surgery.

02 Jul 2024·Zhonghua yi xue za zhi

[Effectiveness and safety of multimodal analgesia in open gastrostomy in patients with end-stage head and neck cancer].

Article

Author: Wu, L L ; Hu, C H ; Chen, Y M ; Wang, G Y ; Chen, H Y ; Yuan, S

Objective: To investigate the effectiveness and safety of multimodal analgesia in patients with end-stage head and neck cancer in open gastrostomy surgery. Methods: This was a randomized controlled trial. From June to December 2023, 50 patients with end-stage head and neck cancer who underwent elective open gastrostomy surgery in Beijing Tongren Hospital Affiliated to Capital Medical University were prospectively selected. The patients were divided into multimodal analgesia group and local anesthesia group using the random number table method according to different anesthesia methods, with 25 cases in each group. In multimodal analgesia group, a multimodal analgesia regimen was adopted: ultrasound-guided abdominal wall nerve block (rectus sheath block and transverse abdominis plane block)+intravenous injection of oxycodone+intravenous injection of flurbiprofen axetil and dexamethasone. In local anesthesia group, local infiltration anesthesia with ropivacaine was adopted. The main outcome measure was the incidence of intraoperative pain numeric rating scale (NRS) score>3 points in the two groups. The secondary observation indicators included NRS score and hemodynamic indexes [mean arterial pressure (MAP) and heart rate (HR)] at various time points during surgery [before anesthesia (T0), at the time of incision (T1), 10 minutes after surgery (T2), during gastric body traction (T3), and at the end of surgery (T4)], incidence of adverse reactions, postoperative patient satisfaction score, as well as the NRS scores at rest and activity (coughing) within 24 hours after surgery. Results: The multimodal analgesia group included 21 males and 4 females, aged (61.4±9.9) years. There were 19 males and 6 females in the local anesthesia group, aged (58.6±10.8) years. The incidence of intraoperative NRS score>3 points and the incidence of salvage analgesia in the multimodal analgesia group were both 12.0% (3/25), which were lower than 60.0% (15/25) in the local anesthesia group, and the differences were statistically significant (all P<0.001); The NRS score [M (Q₁, Q₃)] at T3 in the multimodal analgesia group was 2 (2, 3) points, which were lower than 5 (3, 6) points in the local anesthesia group (P<0.05). There were smaller variabilities in MAP and HR in the multimodal analgesia group than those in the local anesthesia group (all P<0.05). The incidence of intraoperative tachycardia, surgical traction reaction, and nausea in the multimodal analgesia group was lower than that in the local anesthesia group (all P<0.05). The postoperative satisfaction score of patients in the multimodal analgesia group was (9.25±0.71) points, which were higher than (7.33±0.87) points in the local anesthesia group (P<0.001). NRS score during postoperative activity within 24 hours in the multimodal analgesia group were (2.36±0.75) points, which were lower than (3.03±0.81) points of the local anesthesia group (P=0.005). No adverse reactions such as urinary retention, nausea, vomiting and dizziness occurred in both groups. Conclusion: Compared with local anesthesia, the multimodal analgesic strategy could provide better analgesic effect and longer duration, better hemodynamic stability, and fewer intraoperative adverse reactions in patients with end-stage head and neck cancer undergoing open gastrostomy.

01 Jun 2024·Journal of Orthopaedics

Analgesic effect and safety of a half-dose transdermal buprenorphine patch after arthroscopic rotator cuff repair

Article

Author: Yan, Yingzhao ; Sheng, Jing ; Ru, Xuanliang ; Qu, Hangbo ; Ni, Libin ; Fu, Yang

ObjectiveTo retrospectively explore the effect of a half-dose buprenorphine transdermal patch for analgesia after arthroscopic rotator cuff repair (ARCR).MethodsThis analysis was performed with clinical data from patients who received unilateral ARCR in our hospital between October 2017 and December 2020. The patients were divided into three groups (30 cases each). In group A (control group), 100 mg flurbiprofen axetil (FA) was administered twice a day for 5 days after surgery. In group B (experimental group), 100 mg FA was administered twice a day for 5 days and half (2.5 mg) of a buprenorphine transdermal patch was applied after surgery; an additional half (2.5 mg) patch was applied 3 days later. In group C (condition control group), 100 mg FA was administered twice a day for 5 days and a 5-mg patch was applied directly after surgery. The visual analog scale (VAS) was administered repeatedly 1 day before surgery and 1, 2, 3, 5, and 14 days after surgery in each group. The simple shoulder test (SST) score, range of shoulder forward elevation (FE), and external rotation (ER) were recorded preoperatively and 12 weeks postoperatively.ResultsVAS scores on postoperative days 3 and 5 were significantly lower in groups B and C than in group A (p < 0.05). The VAS score on postoperative day 14 was significantly lower in group C than in group A (p < 0.05). The difference in VAS score between groups B and C was not significant (p > 0.05). All patients had significantly improved VAS scores, SST scores, FE, and ER at 12 weeks postoperatively.ConclusionThe half-dose buprenorphine transdermal patch had a good analgesic effect with minimal side effects after ARCR and did not delay the recovery of shoulder joint function.

100 Deals associated with Flurbiprofen Axetil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01475	Flurbiprofen Axetil	M01AE09 M02AA19 R02AX01 S01BC04	DB14938

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	JP	Kaken Pharmaceutical Co., Ltd.	27 Mar 1992
Pain, Postoperative	JP	Kaken Pharmaceutical Co., Ltd.	27 Mar 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	CN	Shanxi Pude Pharmaceutical Co., Ltd.	02 Jan 2018
Acute rise of fever	Phase 2	CN	Shanxi Pude Pharmaceutical Co., Ltd.	29 Dec 2017
Acute rise of fever	Phase 2	CN	Beijing Jingke Tailai Technology Co., Ltd.	29 Dec 2017
Pain, Postoperative	Phase 1	CN	GUANGDONG JIABO PHARMACEUTICAL CO LTD	05 Jan 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Anesth Analg	Not Applicable	-	200	Flurbiprofen axetil	bmuskroasn(jbgyjetgle) = qocqyqgiez yrdkdauqkv (lufdcsxsbz ) View more	Positive	01 Oct 2017
				Placebo	bmuskroasn(jbgyjetgle) = mbagjlbxmv yrdkdauqkv (lufdcsxsbz ) View more
NCT02043366 (CTgov)	Not Applicable	Pain \| Anesthesia \| Hyperalgesia	180	Normal saline+Remifentanil (Normal Saline)	djnhilqhfl(kfjbkjkabf) = odncnusyta obrfhacgwi (tsvhgscdup, mflveaitef - lqkqdogovw) View more	-	28 Sep 2015
				Flurbiprofen axetil+Remifentanil (Flurbiprofen AxetilⅠ)	djnhilqhfl(kfjbkjkabf) = bkiugujoqu obrfhacgwi (tsvhgscdup, cqoalrluuh - xoeamfsxcl) View more